Finally, AChEs as an enzyme class are known druggable targets; AChE inhibitors have been used in the treatment of various human diseases, such as myasthenia gravis, Alzheimer’s disease, postoperative ileus, bladder distention and glaucoma [41,42,43,44,45]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.